Myriad Genetics expands AZ and MSD partnership

Science

Myriad Genetics is to expand its partnership with MSD and AstraZeneca to use its BRACAnalysis CDx test to identify men with metastatic, castrate-resistant prostate cancer and germline BRCA mutations who are likely to respond to olaparip. If the study is successful, Myriad will file a supplementary premarket approval application with the FDA for use of BRACAnalysis CDx as a companion diagnostic for the drug for this patient population. BRACAnalysis CDx has already been approved by the FDA as a companion test for olaparip in several ovarian and breast cancer indications.

“Myriad Genetics expands AZ and MSD partnership“

Nicole Lambert, president of Myriad Oncology, said: "There is a significant unmet medical need in men with metastatic, castration-resistant prostate cancer and BRCA1/2 mutations, which is an area where the utility of PARP inhibitors is being explored."

See all the latest jobs in Science
Return to news